Linaprazan glurate
Sponsors
Cinclus Pharma Holding AB (publ), Cinclus Pharma Holding AB
Conditions
BioavailabilityCardiodynamic ECGDrug InteractionErosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)GERDPharmacokineticsSafetySafety Issues
Phase 1
A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate
RecruitingNCT05469854
Start: 2022-07-13End: 2026-11-30Target: 121Updated: 2026-06-17
Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation
CompletedNCT05627518
Start: 2022-11-15End: 2023-01-03Updated: 2025-04-03
Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam
CompletedNCT05633147
Start: 2022-11-27End: 2023-05-30Updated: 2025-01-03
Phase 3
A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter study to evaluate the efficacy and safety of 2 doses of linaprazan glurate compared to lansoprazole in 4 or 8 weeks healing in participants with erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D
RecruitingCTIS2024-518714-31-00
Start: 2025-10-03Target: 382Updated: 2025-11-26
A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter clinical trial to evaluate the efficacy and safety of linaprazan glurate compared to lansoprazole in maintenance of healing in participants with healed erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D
Not yet recruitingCTIS2025-522750-39-00
Target: 12Updated: 2026-04-29